2023 美國癲癇學會年會薈萃報道（四）_Journal of Epilepsy

Authors：

王培宇 , 陸璐 , 陳蕾 , 周東

1. ;

Corresponding?author：

Keywords：

癲癇; 基因治療; 診斷; 神經影像; 個體化治療

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

美國癲癇學會（American Epilepsy Society，AES）年會是每年一度國際癲癇學界及工業界最受關注的會議。本年度的AES年會自2023年12月1日在奧蘭多召開，為期5天，討論了目前最受關注的癲癇學術領域及重點突破。本系列文章將分為五期，分別對大會每日的精彩內容進行薈萃報道：本文對大會第四日學術議程的內容進行了整理匯總，重點內容包括癲癇基因治療、神經影像、癲癇患者個體化治療、停藥指征與時機等。

Citation： 王培宇, 陸璐, 陳蕾, 周東. 2023 美國癲癇學會年會薈萃報道（四）. Journal of Epilepsy, 2024, 10(2): 177-183. doi: Copy

1.	Saemundsen E, Ludvigsson P, Hilmarsdottir I, et al. Autism spectrum disorders in children with seizures in the first year of life - a population-based study. Epilepsia, 2007, 48(9): 1724-1730.
2.	Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. The Lancet. Neurology, 2005, 4(11): 712-717.
3.	Riikonen R. Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs, 2014, 28(4): 279-290.
4.	Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U. S. consensus report. Epilepsia, 2010, 51(10): 2175–2189.
5.	Galanopoulou AS, Mowrey WB, Liu W, et al. Preclinical screening for treatments for infantile spasms in the multiple hit rat model of infantile spasms: an update. neurochemical research, 2017, 42(7): 1949-1961.
6.	Ono T, Moshé SL, Galanopoulou AS. Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms. Epilepsia, 2011, 52(9): 1678-1684.
7.	Briggs SW, Mowrey W, Hall CB, et al. CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms. Epilepsia, 2014, 55(1): 94-102.
8.	Doumlele K, Conway E, Hedlund J, et al. A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms. Epilepsy & Behavior Case Reports, 2016, 6: 67-69.
9.	Raffo E, Coppola A, Ono T, et al. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiology of Disease, 2011, 43(2): 322-329.
10.	Akman O, Briggs SW, Mowrey WB, et al. Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions. Epilepsia, 2021, 62(8): 1985-1999.
11.	Nagarajan B, Gowda VK, Yoganathan S, et al. Landscape of genetic infantile epileptic spasms syndrome-A multicenter cohort of 124 children from India. Epilepsia Open, 2023, 8(4): 1383-1404.
12.	Galanopoulou AS, Moshé SL. Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies. Neurobiology of Disease, 2015, 79: 135-149.
13.	Samfira IMA, Galanopoulou AS, Nariai H, et al. EEG-based spatiotemporal dynamics of fast ripple networks and hubs in infantile epileptic spasms. Epilepsia Open, 2023, 124: 112.
14.	Nariai H, Beal J, Galanopoulou AS, et al. Scalp EEG Ictal gamma and beta activity during infantile spasms: Evidence of focality. Epilepsia, 2017, 58(5): 882-892.
15.	Lucasius C, Grigorovsky V, Nariai H, et al. Biomimetic deep learning networks with applications to epileptic spasms and seizure prediction. IEEE transactions on bio-medical engineering, 2023, 22: 153-162.
16.	Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia, 2003, 44(s10): 11-17.
17.	Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 2014, 55(4): 475-482.
18.	Shultz SR, Cardamone L, Liu YR, et al. Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?. Epilepsia, 2013, 54(7): 1240-1250.
19.	Kim JA, Boyle EJ, Wu AC, et al. Epileptiform activity in traumatic brain injury predicts post-traumatic epilepsy. Annals of Neurology, 2018, 83(4): 858-862.
20.	Bragin A, Li L, Almajano J, et al. Pathologic electrographic changes after experimental traumatic brain injury. Epilepsia, 2016, 57(5): 735-745.
21.	Diamond ML, Ritter AC, Jackson EK, et al. Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development. Epilepsia, 2015, 56(8): 1198-1206.
22.	Diamond ML, Ritter AC, Failla MD, et al. IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia, 2014, 55(7): 1109-1119.
23.	Dennis EL, Baron D, Bartnik-Olson B, et al. ENIGMA brain injury: framework, challenges, and opportunities. Human Brain Mapping, 2022, 43(1): 149-166.
24.	Mazarati A, Medel-Matus JS, Shin D, et al. Disruption of intestinal barrier and endotoxemia after traumatic brain injury: Implications for post-traumatic epilepsy. Epilepsia, 2021, 62(6): 1472-1481.
25.	Medel-Matus JS, Shin D, Sankar R, et al. Diversity of kindling of limbic seizures after lateral fluid percussion injury in the rat. Epilepsia Open, 2021, 6(2): 413-418.
26.	Medel-Matus JS, Simpson CA, Ahdoot AI, et al. Modification of post-traumatic epilepsy by fecal microbiota transfer. Epilepsy & Behavior, 2022, 134: 108860.
27.	Medel-Matus JS, Lagishetty V, Santana-Gomez C, et al. Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia, 2022, 63(7): 1835-1848.
28.	Shultz SR, Wright DK, Zheng P, et al. Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. Brain, 2015, 138(Pt 5): 1297–1313.
29.	Liu SJ, Zheng P, Wright DK, et al. Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. Brain: A Journal of Neurology, 2016, 139(Pt 7): 1919–1938.
30.	Vivekananda U, Novak P, Bello OD, et al. Kv1. 1 channelopathy abolishes presynaptic spike width modulation by subthreshold somatic depolarization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114(9): 2395-2400.
31.	Begum R, Bakiri Y, Volynski KE, et al. Action potential broadening in a presynaptic channelopathy. Nature Communications, 2016, 7: 12102.
32.	Qiu Y, O’Neill N, Maffei B, et al. On-demand cell-autonomous gene therapy for brain circuit disorders. Science (New York, N. Y. ), 2022, 378(6619): 523-532.
33.	Wykes R C, Heeroma J H, Mantoan L, et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Science Translational Medicine, 2012, 4(161): 161ra152.
34.	K?tzel D, Nicholson E, Schorge S, et al. Chemical-genetic attenuation of focal neocortical seizures. Nature Communications, 2014, 5: 3847.
35.	Wandschneider B, Hong SJ, Bernhardt BC, et al. Developmental MRI markers cosegregate juvenile patients with myoclonic epilepsy and their healthy siblings. Neurology, 2019, 93(13): e1272-e1280.
36.	Vollmar C, O’Muircheartaigh J, Barker GJ, et al. Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study. Brain, 2011, 134(Pt 6): 1710–1719.
37.	Caciagli L, Wandschneider B, Xiao F, et al. Abnormal hippocampal structure and function in juvenile myoclonic epilepsy and unaffected siblings. Brain, 2019, 142(9): 2670-2687.
38.	McGinnity C J, Koepp M J, Hammers A, et al. NMDA receptor binding in focal epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry, 2015, 86(10): 1150-1157.
39.	Hammers A, Koepp MJ, Brooks DJ, et al. Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis. Epilepsia, 2005, 46(6): 944-948.
40.	Koepp MJ, Richardson MP, Brooks DJ, et al. Central benzodiazepine/gamma-aminobutyric acid A receptors in idiopathic generalized epilepsy: an [11C]flumazenil positron emission tomography study. Epilepsia, 1997, 38(10): 1089-1097.
41.	Galovic M, de Tisi J, McEvoy AW, et al. Resective surgery prevents progressive cortical thinning in temporal lobe epilepsy. Brain:, 2020, 143(11): 3262-3272.
42.	Galovic M, van Dooren VQH, Postma TS, et al. Progressive cortical thinning in patients with focal epilepsy. JAMA Neurology, 2019, 76(10): 1230-1239.
43.	FX, LC, BW, et al. Identification of different MRI atrophy progression trajectories in epilepsy by subtype and stage inference. Brain, 2023, 146(11).
44.	Yasuda CL, Centeno M, Vollmar C, et al. The effect of topiramate on cognitive fMRI. Epilepsy Research, 2013, 105(1-2): 250-255.
45.	Xiao F, Caciagli L, Wandschneider B, et al. Effects of carbamazepine and lamotrigine on functional magnetic resonance imaging cognitive networks. Epilepsia, 2018, 59(7): 1362-1371.
46.	Xiao F, Caciagli L, Wandschneider B, et al. Effect of anti-seizure medications on functional anatomy of language: a perspective from language functional magnetic resonance imaging. Frontiers in Neuroscience, 2021, 15: 787272.
47.	Wandschneider B, Stretton J, Sidhu M, et al. Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. Neurology, 2014, 83(17): 1508-1512.
48.	Feldmann M, Asselin MC, Liu J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. The Lancet Neurology, 2013, 12(8): 777-785.
49.	Laufs H, Richardson M P, Salek-Haddadi A, et al. Converging PET and fMRI evidence for a common area involved in human focal epilepsies. Neurology, 2011, 77(9): 904-910.
50.	Galovic M, Baudracco I, Wright-Goff E, et al. Association of piriform cortex resection with surgical outcomes in patients with temporal lobe epilepsy. JAMA Neurology, 2019, 76(6): 690-700.
51.	Sone D, Ahmad M, Thompson PJ, et al. Optimal surgical extent for memory and seizure outcome in temporal lobe epilepsy. Annals of Neurology, 2022, 91(1): 131-144.
52.	Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63(6): 1398-1442.
53.	Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63(6): 1349-1397.
54.	Berg AT, Rychlik K, Levy SR, et al. Complete remission of childhood-onset epilepsy: stability and prediction over two decades. Brain, 2014, 137(Pt 12): 3213–3222.
55.	Lamberink HJ, Otte WM, Geerts AT, et al. Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. The Lancet Neurology, 2017, 16(7): 523-531.
56.	Arts WF, Geerts AT, Brouwer OF, et al. Childhood epilepsy with a small number of seizures may be left untreated: an international prospective study. Epileptic Disorders, 2019, 21(2): 141-153.
57.	Berg AT, Levy SR, Testa FM, et al. Long-term seizure remission in childhood absence epilepsy: might initial treatment matter?. Epilepsia, 2014, 55(4): 551-557.
58.	Mytinger JR, Parker W, Rust SW, et al. Prioritizing hormone therapy over vigabatrin as the first treatment for infantile spasms: a quality improvement initiative. Neurology, 2022, 99(19): e2171-e2180.
59.	Hirsch E, French J, Scheffer IE, et al. ILAe definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63(6): 1475-1499.
60.	Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63(6): 1333-1348.
61.	Camfield CS, Berg A, Stephani U, et al. Transition issues for benign epilepsy with centrotemporal spikes, nonlesional focal epilepsy in otherwise normal children, childhood absence epilepsy, and juvenile myoclonic epilepsy. Epilepsia, 2014, 55 Suppl 3: 16–20.
62.	Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurology, 2018, 75(9): 1132-1141.
63.	Volbers B, Walther K, Kurzbuch K, et al. Psychogenic nonepileptic seizures: clinical characteristics and outcome. Brain and Behavior, 2022, 12(5): e2567.
64.	McKenzie P, Oto M, Russell A, et al. Early outcomes and predictors in 260 patients with psychogenic nonepileptic attacks. Neurology, 2010, 74(1): 64-69.
65.	Massot-Tarrús A, Joe Yu Y, AlKhateeb M, et al. Predicting outcome of patients with psychogenic nonepileptic seizures after diagnosis in an epilepsy monitoring unit. Epilepsy & Behavior, 2021, 120: 108004.
66.	Tavakoli Yaraki P, Paredes-Aragon E, Joe Yu Y, et al. Patients with psychogenic nonepileptic seizures and suspected epilepsy: an antiseizure medication reduction study. Epilepsy & Behavior, 2023, 141: 109116.
67.	Baslet G, Seshadri A, Bermeo-Ovalle A, et al. Psychogenic Non-epileptic Seizures: an Updated Primer. Psychosomatics, 2016, 57(1): 1-17.
68.	Kerr WT, Janio EA, Le JM, et al. Diagnostic delay in psychogenic seizures and the association with anti-seizure medication trials. Seizure, 2016, 40: 123-126.
69.	Carlson P, Nicholson Perry K. Psychological interventions for psychogenic non-epileptic seizures: A meta-analysis. Seizure, 2017, 45: 142-150.
70.	LaFrance WC, Baird GL, Barry JJ, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry, 2014, 71(9): 997-1005.
71.	Goldstein LH, Robinson EJ, Mellers JDC, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. The Lancet. Psychiatry, 2020, 7(6): 491-505.
72.	Hsieh JK, Pucci FG, Sundar SJ, et al. Beyond seizure freedom: Dissecting long-term seizure control after surgical resection for drug-resistant epilepsy. Epilepsia, 2023, 64(1): 103-113.
73.	Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology, 2020, 95(9): e1244-e1256.
74.	Gloss D, Pargeon K, Pack A, et al. Antiseizure Medication withdrawal in seizure-free patients: practice advisory update summary: report of the aan guideline subcommittee. Neurology, 2021, 97(23): 1072-1081.
75.	Kerling F, Pauli E, Lorber B, et al. Drug withdrawal after successful epilepsy surgery: how safe is it?. Epilepsy & Behavior, 2009, 15(4): 476-480.
76.	Boshuisen K, Arzimanoglou A, Cross J H, et al. Timing of antiepileptic drug withdrawal and long-term seizure outcome after paediatric epilepsy surgery (TimeToStop): a retrospective observational study. The Lancet. Neurology, 2012, 11(9): 784-791.
77.	Yardi R, Irwin A, Kayyali H, et al. Reducing versus stopping antiepileptic medications after temporal lobe surgery. Annals of Clinical and Translational Neurology, 2014, 1(2): 115-123.
78.	Lamberink HJ, Boshuisen K, Otte WM, et al. Individualized prediction of seizure relapse and outcomes following antiepileptic drug withdrawal after pediatric epilepsy surgery. Epilepsia, 2018, 59(3): e28-e33.
79.	Ferreira-Atuesta C, de Tisi J, McEvoy AW, et al. Predictive models for starting antiseizure medication withdrawal following epilepsy surgery in adults. Brain, 2023, 146(6): 2389-2398.
80.	Jehi L, Yehia L, Peterson C, et al. Preliminary report: Late seizure recurrence years after epilepsy surgery may be associated with alterations in brain tissue transcriptome. Epilepsia Open, 2018, 3(2): 299-304.
81.	Louis S, Busch RM, Lal D, et al. Genetic and molecular features of seizure-freedom following surgical resections for focal epilepsy: a pilot study. Frontiers in Neurology, 2022, 13: 942643.
82.	Brooks-Kayal A. Molecular mechanisms of cognitive and behavioral comorbidities of epilepsy in children. Epilepsia, 2011, 52(Suppl 1): 13-20.
83.	Jones JE, Asato MR, Brown MG, et al. Epilepsy Benchmarks Area IV: Limit or prevent adverse consequence of seizures and their treatment across the life span. Epilepsy Currents, 2020, 20(suppl 1): 31S-39S.
84.	Dang H, Khan A B, Gadgil N, et al. Behavioral improvements following lesion resection for pediatric epilepsy: pediatric psychosurgery?. Pediatric Neurosurgery, 2023, 58(2): 80-88.
85.	Gil B, Smith J, Tang Y, et al. Beyond seizure control: treating comorbidities in epilepsy via targeting of the p2x7 receptor. International Journal of Molecular Sciences, 2022, 23(4): 2380.
86.	Lossius MI, Hessen E, Mowinckel P, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia, 2008, 49(3): 455-463.
87.	Randomised study of antiepileptic drug withdrawal in patients in remission. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Lancet (London, England), 1991, 337(8751): 1175-1180.
88.	Callaghan N, Garrett A, Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. The New England Journal of Medicine, 1988, 318(15): 942-946.
89.	Thurston JH, Thurston DL, Hixon BB, et al. Prognosis in childhood epilepsy: additional follow-up of 148 children 15 to 23 years after withdrawal of anticonvulsant therapy. The New England Journal of Medicine, 1982, 306(14): 831-836.
90.	Sillanp?? M, Schmidt D. Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population-based study of childhood-onset epilepsy. Epilepsy & Behavior:E& B, 2006, 8(4): 713-719.
91.	Schmidt D, L?scher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurologica Scandinavica, 2005, 111(5): 291-300.
92.	Chadwick D, Taylor J, Johnson T. Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. The MRC Antiepileptic Drug Withdrawal Group. Epilepsia, 1996, 37(11): 1043-1050.

1. Saemundsen E, Ludvigsson P, Hilmarsdottir I, et al. Autism spectrum disorders in children with seizures in the first year of life - a population-based study. Epilepsia, 2007, 48(9): 1724-1730.
2. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. The Lancet. Neurology, 2005, 4(11): 712-717.
3. Riikonen R. Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs, 2014, 28(4): 279-290.
4. Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U. S. consensus report. Epilepsia, 2010, 51(10): 2175–2189.
5. Galanopoulou AS, Mowrey WB, Liu W, et al. Preclinical screening for treatments for infantile spasms in the multiple hit rat model of infantile spasms: an update. neurochemical research, 2017, 42(7): 1949-1961.
6. Ono T, Moshé SL, Galanopoulou AS. Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms. Epilepsia, 2011, 52(9): 1678-1684.
7. Briggs SW, Mowrey W, Hall CB, et al. CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms. Epilepsia, 2014, 55(1): 94-102.
8. Doumlele K, Conway E, Hedlund J, et al. A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms. Epilepsy & Behavior Case Reports, 2016, 6: 67-69.
9. Raffo E, Coppola A, Ono T, et al. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiology of Disease, 2011, 43(2): 322-329.
10. Akman O, Briggs SW, Mowrey WB, et al. Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions. Epilepsia, 2021, 62(8): 1985-1999.
11. Nagarajan B, Gowda VK, Yoganathan S, et al. Landscape of genetic infantile epileptic spasms syndrome-A multicenter cohort of 124 children from India. Epilepsia Open, 2023, 8(4): 1383-1404.
12. Galanopoulou AS, Moshé SL. Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies. Neurobiology of Disease, 2015, 79: 135-149.
13. Samfira IMA, Galanopoulou AS, Nariai H, et al. EEG-based spatiotemporal dynamics of fast ripple networks and hubs in infantile epileptic spasms. Epilepsia Open, 2023, 124: 112.
14. Nariai H, Beal J, Galanopoulou AS, et al. Scalp EEG Ictal gamma and beta activity during infantile spasms: Evidence of focality. Epilepsia, 2017, 58(5): 882-892.
15. Lucasius C, Grigorovsky V, Nariai H, et al. Biomimetic deep learning networks with applications to epileptic spasms and seizure prediction. IEEE transactions on bio-medical engineering, 2023, 22: 153-162.
16. Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia, 2003, 44(s10): 11-17.
17. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 2014, 55(4): 475-482.
18. Shultz SR, Cardamone L, Liu YR, et al. Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?. Epilepsia, 2013, 54(7): 1240-1250.
19. Kim JA, Boyle EJ, Wu AC, et al. Epileptiform activity in traumatic brain injury predicts post-traumatic epilepsy. Annals of Neurology, 2018, 83(4): 858-862.
20. Bragin A, Li L, Almajano J, et al. Pathologic electrographic changes after experimental traumatic brain injury. Epilepsia, 2016, 57(5): 735-745.
21. Diamond ML, Ritter AC, Jackson EK, et al. Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development. Epilepsia, 2015, 56(8): 1198-1206.
22. Diamond ML, Ritter AC, Failla MD, et al. IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia, 2014, 55(7): 1109-1119.
23. Dennis EL, Baron D, Bartnik-Olson B, et al. ENIGMA brain injury: framework, challenges, and opportunities. Human Brain Mapping, 2022, 43(1): 149-166.
24. Mazarati A, Medel-Matus JS, Shin D, et al. Disruption of intestinal barrier and endotoxemia after traumatic brain injury: Implications for post-traumatic epilepsy. Epilepsia, 2021, 62(6): 1472-1481.
25. Medel-Matus JS, Shin D, Sankar R, et al. Diversity of kindling of limbic seizures after lateral fluid percussion injury in the rat. Epilepsia Open, 2021, 6(2): 413-418.
26. Medel-Matus JS, Simpson CA, Ahdoot AI, et al. Modification of post-traumatic epilepsy by fecal microbiota transfer. Epilepsy & Behavior, 2022, 134: 108860.
27. Medel-Matus JS, Lagishetty V, Santana-Gomez C, et al. Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia, 2022, 63(7): 1835-1848.
28. Shultz SR, Wright DK, Zheng P, et al. Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. Brain, 2015, 138(Pt 5): 1297–1313.
29. Liu SJ, Zheng P, Wright DK, et al. Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. Brain: A Journal of Neurology, 2016, 139(Pt 7): 1919–1938.
30. Vivekananda U, Novak P, Bello OD, et al. Kv1. 1 channelopathy abolishes presynaptic spike width modulation by subthreshold somatic depolarization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114(9): 2395-2400.
31. Begum R, Bakiri Y, Volynski KE, et al. Action potential broadening in a presynaptic channelopathy. Nature Communications, 2016, 7: 12102.
32. Qiu Y, O’Neill N, Maffei B, et al. On-demand cell-autonomous gene therapy for brain circuit disorders. Science (New York, N. Y. ), 2022, 378(6619): 523-532.
33. Wykes R C, Heeroma J H, Mantoan L, et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Science Translational Medicine, 2012, 4(161): 161ra152.
34. K?tzel D, Nicholson E, Schorge S, et al. Chemical-genetic attenuation of focal neocortical seizures. Nature Communications, 2014, 5: 3847.
35. Wandschneider B, Hong SJ, Bernhardt BC, et al. Developmental MRI markers cosegregate juvenile patients with myoclonic epilepsy and their healthy siblings. Neurology, 2019, 93(13): e1272-e1280.
36. Vollmar C, O’Muircheartaigh J, Barker GJ, et al. Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study. Brain, 2011, 134(Pt 6): 1710–1719.
37. Caciagli L, Wandschneider B, Xiao F, et al. Abnormal hippocampal structure and function in juvenile myoclonic epilepsy and unaffected siblings. Brain, 2019, 142(9): 2670-2687.
38. McGinnity C J, Koepp M J, Hammers A, et al. NMDA receptor binding in focal epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry, 2015, 86(10): 1150-1157.
39. Hammers A, Koepp MJ, Brooks DJ, et al. Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis. Epilepsia, 2005, 46(6): 944-948.
40. Koepp MJ, Richardson MP, Brooks DJ, et al. Central benzodiazepine/gamma-aminobutyric acid A receptors in idiopathic generalized epilepsy: an [11C]flumazenil positron emission tomography study. Epilepsia, 1997, 38(10): 1089-1097.
41. Galovic M, de Tisi J, McEvoy AW, et al. Resective surgery prevents progressive cortical thinning in temporal lobe epilepsy. Brain:, 2020, 143(11): 3262-3272.
42. Galovic M, van Dooren VQH, Postma TS, et al. Progressive cortical thinning in patients with focal epilepsy. JAMA Neurology, 2019, 76(10): 1230-1239.
43. FX, LC, BW, et al. Identification of different MRI atrophy progression trajectories in epilepsy by subtype and stage inference. Brain, 2023, 146(11).
44. Yasuda CL, Centeno M, Vollmar C, et al. The effect of topiramate on cognitive fMRI. Epilepsy Research, 2013, 105(1-2): 250-255.
45. Xiao F, Caciagli L, Wandschneider B, et al. Effects of carbamazepine and lamotrigine on functional magnetic resonance imaging cognitive networks. Epilepsia, 2018, 59(7): 1362-1371.
46. Xiao F, Caciagli L, Wandschneider B, et al. Effect of anti-seizure medications on functional anatomy of language: a perspective from language functional magnetic resonance imaging. Frontiers in Neuroscience, 2021, 15: 787272.
47. Wandschneider B, Stretton J, Sidhu M, et al. Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. Neurology, 2014, 83(17): 1508-1512.
48. Feldmann M, Asselin MC, Liu J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. The Lancet Neurology, 2013, 12(8): 777-785.
49. Laufs H, Richardson M P, Salek-Haddadi A, et al. Converging PET and fMRI evidence for a common area involved in human focal epilepsies. Neurology, 2011, 77(9): 904-910.
50. Galovic M, Baudracco I, Wright-Goff E, et al. Association of piriform cortex resection with surgical outcomes in patients with temporal lobe epilepsy. JAMA Neurology, 2019, 76(6): 690-700.
51. Sone D, Ahmad M, Thompson PJ, et al. Optimal surgical extent for memory and seizure outcome in temporal lobe epilepsy. Annals of Neurology, 2022, 91(1): 131-144.
52. Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63(6): 1398-1442.
53. Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63(6): 1349-1397.
54. Berg AT, Rychlik K, Levy SR, et al. Complete remission of childhood-onset epilepsy: stability and prediction over two decades. Brain, 2014, 137(Pt 12): 3213–3222.
55. Lamberink HJ, Otte WM, Geerts AT, et al. Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. The Lancet Neurology, 2017, 16(7): 523-531.
56. Arts WF, Geerts AT, Brouwer OF, et al. Childhood epilepsy with a small number of seizures may be left untreated: an international prospective study. Epileptic Disorders, 2019, 21(2): 141-153.
57. Berg AT, Levy SR, Testa FM, et al. Long-term seizure remission in childhood absence epilepsy: might initial treatment matter?. Epilepsia, 2014, 55(4): 551-557.
58. Mytinger JR, Parker W, Rust SW, et al. Prioritizing hormone therapy over vigabatrin as the first treatment for infantile spasms: a quality improvement initiative. Neurology, 2022, 99(19): e2171-e2180.
59. Hirsch E, French J, Scheffer IE, et al. ILAe definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63(6): 1475-1499.
60. Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63(6): 1333-1348.
61. Camfield CS, Berg A, Stephani U, et al. Transition issues for benign epilepsy with centrotemporal spikes, nonlesional focal epilepsy in otherwise normal children, childhood absence epilepsy, and juvenile myoclonic epilepsy. Epilepsia, 2014, 55 Suppl 3: 16–20.
62. Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurology, 2018, 75(9): 1132-1141.
63. Volbers B, Walther K, Kurzbuch K, et al. Psychogenic nonepileptic seizures: clinical characteristics and outcome. Brain and Behavior, 2022, 12(5): e2567.
64. McKenzie P, Oto M, Russell A, et al. Early outcomes and predictors in 260 patients with psychogenic nonepileptic attacks. Neurology, 2010, 74(1): 64-69.
65. Massot-Tarrús A, Joe Yu Y, AlKhateeb M, et al. Predicting outcome of patients with psychogenic nonepileptic seizures after diagnosis in an epilepsy monitoring unit. Epilepsy & Behavior, 2021, 120: 108004.
66. Tavakoli Yaraki P, Paredes-Aragon E, Joe Yu Y, et al. Patients with psychogenic nonepileptic seizures and suspected epilepsy: an antiseizure medication reduction study. Epilepsy & Behavior, 2023, 141: 109116.
67. Baslet G, Seshadri A, Bermeo-Ovalle A, et al. Psychogenic Non-epileptic Seizures: an Updated Primer. Psychosomatics, 2016, 57(1): 1-17.
68. Kerr WT, Janio EA, Le JM, et al. Diagnostic delay in psychogenic seizures and the association with anti-seizure medication trials. Seizure, 2016, 40: 123-126.
69. Carlson P, Nicholson Perry K. Psychological interventions for psychogenic non-epileptic seizures: A meta-analysis. Seizure, 2017, 45: 142-150.
70. LaFrance WC, Baird GL, Barry JJ, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry, 2014, 71(9): 997-1005.
71. Goldstein LH, Robinson EJ, Mellers JDC, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. The Lancet. Psychiatry, 2020, 7(6): 491-505.
72. Hsieh JK, Pucci FG, Sundar SJ, et al. Beyond seizure freedom: Dissecting long-term seizure control after surgical resection for drug-resistant epilepsy. Epilepsia, 2023, 64(1): 103-113.
73. Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology, 2020, 95(9): e1244-e1256.
74. Gloss D, Pargeon K, Pack A, et al. Antiseizure Medication withdrawal in seizure-free patients: practice advisory update summary: report of the aan guideline subcommittee. Neurology, 2021, 97(23): 1072-1081.
75. Kerling F, Pauli E, Lorber B, et al. Drug withdrawal after successful epilepsy surgery: how safe is it?. Epilepsy & Behavior, 2009, 15(4): 476-480.
76. Boshuisen K, Arzimanoglou A, Cross J H, et al. Timing of antiepileptic drug withdrawal and long-term seizure outcome after paediatric epilepsy surgery (TimeToStop): a retrospective observational study. The Lancet. Neurology, 2012, 11(9): 784-791.
77. Yardi R, Irwin A, Kayyali H, et al. Reducing versus stopping antiepileptic medications after temporal lobe surgery. Annals of Clinical and Translational Neurology, 2014, 1(2): 115-123.
78. Lamberink HJ, Boshuisen K, Otte WM, et al. Individualized prediction of seizure relapse and outcomes following antiepileptic drug withdrawal after pediatric epilepsy surgery. Epilepsia, 2018, 59(3): e28-e33.
79. Ferreira-Atuesta C, de Tisi J, McEvoy AW, et al. Predictive models for starting antiseizure medication withdrawal following epilepsy surgery in adults. Brain, 2023, 146(6): 2389-2398.
80. Jehi L, Yehia L, Peterson C, et al. Preliminary report: Late seizure recurrence years after epilepsy surgery may be associated with alterations in brain tissue transcriptome. Epilepsia Open, 2018, 3(2): 299-304.
81. Louis S, Busch RM, Lal D, et al. Genetic and molecular features of seizure-freedom following surgical resections for focal epilepsy: a pilot study. Frontiers in Neurology, 2022, 13: 942643.
82. Brooks-Kayal A. Molecular mechanisms of cognitive and behavioral comorbidities of epilepsy in children. Epilepsia, 2011, 52(Suppl 1): 13-20.
83. Jones JE, Asato MR, Brown MG, et al. Epilepsy Benchmarks Area IV: Limit or prevent adverse consequence of seizures and their treatment across the life span. Epilepsy Currents, 2020, 20(suppl 1): 31S-39S.
84. Dang H, Khan A B, Gadgil N, et al. Behavioral improvements following lesion resection for pediatric epilepsy: pediatric psychosurgery?. Pediatric Neurosurgery, 2023, 58(2): 80-88.
85. Gil B, Smith J, Tang Y, et al. Beyond seizure control: treating comorbidities in epilepsy via targeting of the p2x7 receptor. International Journal of Molecular Sciences, 2022, 23(4): 2380.
86. Lossius MI, Hessen E, Mowinckel P, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia, 2008, 49(3): 455-463.
87. Randomised study of antiepileptic drug withdrawal in patients in remission. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Lancet (London, England), 1991, 337(8751): 1175-1180.
88. Callaghan N, Garrett A, Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. The New England Journal of Medicine, 1988, 318(15): 942-946.
89. Thurston JH, Thurston DL, Hixon BB, et al. Prognosis in childhood epilepsy: additional follow-up of 148 children 15 to 23 years after withdrawal of anticonvulsant therapy. The New England Journal of Medicine, 1982, 306(14): 831-836.
90. Sillanp?? M, Schmidt D. Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population-based study of childhood-onset epilepsy. Epilepsy & Behavior:E& B, 2006, 8(4): 713-719.
91. Schmidt D, L?scher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurologica Scandinavica, 2005, 111(5): 291-300.
92. Chadwick D, Taylor J, Johnson T. Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. The MRC Antiepileptic Drug Withdrawal Group. Epilepsia, 1996, 37(11): 1043-1050.

Journal of Epilepsy

2023 美國癲癇學會年會薈萃報道（四）

Abstract Full text Figures/Tables Video References Cited by

Format

Content